[Clinical Analysis of Autologous Hematopoietic Stem Cell Transplantation in Treatment of Mantle Cell Lymphoma: a Multicenter Retrospective Study].

OBJECTIVE: To investigate the efficacy and prognostic factors of autologous hematopoietic stem cell transplantation (ASCT) in the treatment of mantle cell lymphoma (MCL) in the real world. METHODS: The clinical data of 85 MCL patients who underwent ASCT in Peking University Third Hospital and other Chinese centers from January 2005 to December 2021 were retrospectively analyzed. The patients were treated with rituximab-based chemotherapy before transplantation, and the effects of clinical characteristics, treatment regimens and biological indicators on overall survival (OS) and progression-free survival (PFS) were observed. RESULTS: =0.049) were independent adverse prognostic factors for OS. CONCLUSION: ASCT consolidation therapy plays an important role in improving PFS and OS of MCL patients with young age and good general condition, especially for those with MIPI-c low/low-intermediate risk, receiving maintenance therapy with new drugs after ASCT, and non-relapsed/refractory state.